bevacizumab,adagrasib,tucatinib,trastuzumab deruxtecan,regorafenib,encorafenib,cetuximab,ruxolitinib,sotorasib,panitumumab,fruquintinib,pertuzumab
roche,mirati therapeutics,daiichi sankyo,astrazeneca,incyte,pfizer,eli lilly,bayer,novartis,amgen,hutchmed,seagen
[]
really outstanding abstract discussion today by with these great slides outlining all treatment options for late line mcrc #gi23 
GI medical oncologist, Associate Prof Univ of WI, public health, proud Midwesterner, opinions mine  FCOI: https://t.co/vHScVEaG0b